Biotech Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 November 6, 2026
Biotech Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update November 6, 2026
Biotech HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE November 6, 2026
Biotech Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 November 5, 2026
Biotech Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026 November 5, 2026